Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34


Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389. Epub 2012 Jul 30.


Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.

Lacey JV Jr, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG.

Int J Cancer. 2012 Oct 15;131(8):1921-9. doi: 10.1002/ijc.27457. Epub 2012 Mar 14.


A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.

Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398-409. doi: 10.1158/1055-9965.EPI-11-0206. Epub 2011 May 20. Erratum in: Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1390-1.


Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DA, Chatterjee N, Langholz B.

J Clin Oncol. 2010 Feb 10;28(5):788-92. doi: 10.1200/JCO.2009.24.1315. Epub 2010 Jan 11.


Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.

Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME.

Cancer. 2008 Oct 15;113(8):2073-81. doi: 10.1002/cncr.23808.


PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.

Lacey JV Jr, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME.

Cancer Res. 2008 Jul 15;68(14):6014-20. doi: 10.1158/0008-5472.CAN-08-1154.


Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification.

Sherman ME, Ronnett BM, Ioffe OB, Richesson DA, Rush BB, Glass AG, Chatterjee N, Duggan MA, Lacey JV Jr.

Int J Gynecol Pathol. 2008 Jul;27(3):318-25. doi: 10.1097/PGP.0b013e3181659167.


Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Lacey JV Jr, Ioffe OB, Ronnett BM, Rush BB, Richesson DA, Chatterjee N, Langholz B, Glass AG, Sherman ME.

Br J Cancer. 2008 Jan 15;98(1):45-53. Epub 2007 Nov 20.


Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions.

Gravitt PE, van Doorn LJ, Quint W, Schiffman M, Hildesheim A, Glass AG, Rush BB, Hellman J, Sherman ME, Burk RD, Wang SS.

J Clin Microbiol. 2007 Oct;45(10):3245-50. Epub 2007 Aug 15.


Abnormal outcomes following cervical cancer screening: event duration and health utility loss.

Insinga RP, Glass AG, Myers ER, Rush BB.

Med Decis Making. 2007 Jul-Aug;27(4):414-22. Epub 2007 Jun 21.


Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study.

Pratt MM, Sirajuddin P, Poirier MC, Schiffman M, Glass AG, Scott DR, Rush BB, Olivero OA, Castle PE.

Mutat Res. 2007 Nov 1;624(1-2):114-23. Epub 2007 May 5.


Human papillomavirus prevalence in women who have and have not undergone hysterectomies.

Castle PE, Schiffman M, Glass AG, Rush BB, Scott DR, Wacholder S, Dunn A, Burk RD.

J Infect Dis. 2006 Dec 15;194(12):1702-5. Epub 2006 Nov 3.


Cervical HPV DNA detection as a predictor of a recurrent SIL diagnosis among untreated women.

Castle PE, Zemlo TR, Burk RD, Scott DR, Sherman ME, Lorincz AT, Kurman RJ, Glass AG, Rush BB, Liaw KL, Schiffman M.

J Low Genit Tract Dis. 2001 Jul;5(3):138-43.


Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201].

Insinga RP, Glass AG, Rush BB.

Health Policy. 2006 Aug;77(3):245-6. Epub 2005 Nov 16. No abstract available.


The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.


Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer.

Castle PE, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz AT.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1311-4.


The health care costs of cervical human papillomavirus--related disease.

Insinga RP, Glass AG, Rush BB.

Am J Obstet Gynecol. 2004 Jul;191(1):114-20.


Diagnoses and outcomes in cervical cancer screening: a population-based study.

Insinga RP, Glass AG, Rush BB.

Am J Obstet Gynecol. 2004 Jul;191(1):105-13.


Pap screening in a U.S. health plan.

Insinga RP, Glass AG, Rush BB.

Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):355-60.


Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.

Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M.

J Clin Microbiol. 2003 Sep;41(9):4022-30.


Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.


Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.

Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR, Rush BB, Demuth F, Schiffman M.

Cancer. 2002 Nov 15;95(10):2145-51.


A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.

Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M.

J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14.


Viral load of human papillomavirus and risk of CIN3 or cervical cancer.

Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M.

Lancet. 2002 Jul 20;360(9328):228-9.


Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions.

Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, Tabor D, Schiffman M.

J Natl Cancer Inst. 1999 Jun 2;91(11):954-60.


"ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection.

Sherman ME, Tabbara SO, Scott DR, Kurman RJ, Glass AG, Manos MM, Burk RD, Rush BB, Schiffman M.

Mod Pathol. 1999 Apr;12(4):335-42.


Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.

Hildesheim A, Schiffman M, Scott DR, Marti D, Kissner T, Sherman ME, Glass AG, Manos MM, Lorincz AT, Kurman RJ, Buckland J, Rush BB, Carrington M.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1035-41.


Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.

Hildesheim A, Schiffman MH, Tsukui T, Swanson CA, Lucci J 3rd, Scott DR, Glass AG, Rush BB, Lorincz AT, Corrigan A, Burk RD, Helgesen K, Houghten RA, Sherman ME, Kurman RJ, Berzofsky JA, Kramer TR.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):807-13.


Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.

Tsukui T, Hildesheim A, Schiffman MH, Lucci J 3rd, Contois D, Lawler P, Rush BB, Lorincz AT, Corrigan A, Burk RD, Qu W, Marshall MA, Mann D, Carrington M, Clerici M, Shearer GM, Carbone DP, Scott DR, Houghten RA, Berzofsky JA.

Cancer Res. 1996 Sep 1;56(17):3967-74.


Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications.

Doody MM, Linet MS, Glass AG, Curtis RE, Pottern LM, Rush BB, Boice JD Jr, Fraumeni JF Jr, Friedman GD.

Epidemiology. 1996 Mar;7(2):131-9.


Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types.

Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kuman RJ, Kiviat NB, Stoler M, Glass AG, Rush BB.

Am J Clin Pathol. 1994 Aug;102(2):182-7.


Persistence of type-specific human papillomavirus infection among cytologically normal women.

Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al.

J Infect Dis. 1994 Feb;169(2):235-40.


Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon.

Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR, Cadell DM, Kurman RJ, Manos MM.

Sex Transm Dis. 1993 Sep-Oct;20(5):274-8.


Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia.

Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, et al.

J Natl Cancer Inst. 1993 Jun 16;85(12):958-64.


Supplemental Content

Support Center